← Back to headlines
Compass Therapeutics Stock Plunges After Drug Fails to Meet Endpoint
Compass Therapeutics' stock fell sharply after its drug, tovecimig, failed to meet its overall survival endpoint in a clinical trial.
27 Apr, 19:53 — 27 Apr, 19:53
Sources
Showing 1 of 1 sources
Related Stories
'Astronauts back on Earth': Artemis II crew splashes down after record-breaking moon flyby – video
just now
Rare Plant Species Discovered in Bicol Natural Park, Philippines
just now
Study reveals Neanderthal children grew faster than modern humans
just now
Mokslininkas Čeburnis – apie dirbtinį intelektą: yra vienas „paslėptas akmuo“, apie kurį niekas nekalba
8m ago